AzTrials
AzTrials

Severe HaemophiliaFRATHEMONCT03299699

Quality of Life and Adjustment Among Siblings of Children and Adolescents With Severe Hemophilia

An observational study of Severe Haemophilia, run by Assistance Publique Hopitaux De Marseille at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Severe hemophilia is a rare and chronic disease characterized by spontaneous bleedings from early childhood, which may lead to various complications especially in joints. The diagnosis of this disease, but also its long term care have an impact on the relatives of the affected persons, including the siblings who bear… Read more about this study

Who is it for?
Ages 8 to 18 years
Conditions the study is for
Severe Haemophilia
How many people
30 participants
Where
1 siteFrance
Study dates
15 Mar 2020to 1 May 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: siblings of children and adolescents with severe hemophilia

Who may be able to join

  • Sibling (brother, sister, half-brother or half-sister) of older children or adolescents included in the TRANSHEMO study, who lives in the same home)
  • Sibling aged 8-18 years old
  • Sibling affiliated to the French social security system
  • Sibling whose parents are not opposed to the participation in the study

Who cannot join

  • Sibling (brother, sister, half-brother or half-sister) of older children or adolescents who are not included in the TRANSHEMO study)
  • Sibling aged under 8 or over 18 years old
  • Sibling not affiliated to the French social security system
  • Sibling whose parents are opposed to the participation in the study
  • Sibling with difficulties reading and writing
  • Sibling with learning disabilities

Trial locations and contacts

1 site in 1 country.

France1 site
  • Hôpital de la Timone Assistance Publique Hôpitaux de Marseille

    Marseille, 13354

Other trials in France

About this study

Official title: FRATHEMO: Quality of Life and Adjustment Among Siblings of Children and Adolescents With Severe Hemophilia.

Severe hemophilia is a rare and chronic disease characterized by spontaneous bleedings from early childhood, which may lead to various complications especially in joints. The diagnosis of this disease, but also its long term care have an impact on the relatives of the affected persons, including the siblings who bear daily the cognitive, emotional and social impacts of the disease.

Studies conducted in the framework of pediatric chronic diseases showed that siblings of affected children presented a higher prevalence of physical and psychological troubles (emotional distress, behavioral disorders, etc.) than siblings who were not concerned by a disease. Few studies have been conducted in the framework of severe hemophilia, and to our knowledge, no study addresses this issue in France.

Read the detailed description

-The assessment of the quality of life would allow assessing both positive and negative impacts, by exploring in a global manner the children and adolescents functioning in various domains (physical and psychological well-being, relations with parents and friends, school…).

Regarding the specific context of hemophilia:

  • Few studies have been conducted on the experience of severe hemophilia of a young patient by the siblings, and to our knowledge, no studies have been conducted in France on this topic.
  • There are numerous studies concerning the impact of chronic diseases such as diabetes or cancer of a child on the siblings, contrary to those concerning rare diseases. Hemophilia, a frequent disease among rare diseases, might be an interesting model in order to understand the impact of this type of disorder on the functioning of the siblings.
  • Contrary to insufficiently treated hemophilia potentially leading to disability, well-treated hemophilia might be considered as an at-risk disorder. In this specific context, the representation of the disease by the siblings might be singular.
  • Parents are the major actors of the surveillance of the affected young patient in the everyday life. The transfer of parental responsibilities to healthy siblings, and its impact on the fraternal relationships might therefore be increased. Gender might have a specific modulating role on these elements (risk of transmission in female and different representation of the social role).
  • Results presented in the literature are reported from studies whose representativeness of the study sample (or sample size) is questionable. The cohort of the French National Network FranceCoag represents at an international level a rare exhaustive population of persons with severe hemophilia followed over time.

Objectives The main objective of this study is to understand the mechanisms involved in the quality of the siblings' functioning and interactions in the context of severe hemophilia, in order to be able to propose adapted support modes.

The secondary (and operational) objectives are:

  • To assess the impact of the functioning and interactions of the family on the quality of life (considered as a marker of the global health) reported by the siblings
  • To compare the quality of life reported by siblings of children and adolescents with severe hemophilia, with the quality of life of the patients themselves, and with published reference values (age and gender-matched controls from the general population)
  • To assess the emotional and social adjustment (behavioral disorders, academic success), which represents a mediator of the quality of life, among siblings
  • To assess the moderating effects of gender, age, rank among siblings, time since diagnosis, quality of social support received, skills acquired to manage emotions, on quality of life as well as on the emotional and social adjustment
  • To highlight clusters of siblings with different profiles of quality of life
  • To propose tools, meetings and training sessions in order to support concerned families

Material and methods This study is complementary to the multicentric, observational, cross-sectional, TRANSHEMO study. TRANSHEMO focuses on the issues surrounding the transition into adulthood among young persons with severe hemophilia in France. This study also aims to identify some of the socio- cognitive, emotional, and familial determinants of a good transition into adulthood. Perceptions of older children and adolescents (aged 14-17 years old) with severe hemophilia and those of young adults (aged 20-29 years old) will be described et compared, regarding their expectations and their feelings about growing into adulthood.

The present study which is also a multicentric, observational, cross-sectional study, proposes to include the siblings [i.e. brothers, sisters, half-brothers and half-sisters (aged 8-18 years old)] of the older children and adolescents included in the TRANSHEMO study, living in the same household. The investigators will ask them to fill-up a booklet with several questionnaires, focused on quality of life. This study will allow to have preliminary results in order to extend the project to another age group of children with severe hemophilia and their siblings.

Expected results This study will allow to comprehend what the impact of the disease on the siblings could be, which is of particular interest in the global approach whose goal is to take care of and to support the affected persons and their relatives. The identification of difficulties among siblings and of their determinants will allow to detect children at risk of adjustment problem, in order to offer them an adapted support, but also to develop specific tools to support the families (brochures, meetings, therapeutic education activities).

Medical subject headings
Hemophilia A

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Global quality of life

    Kidscreen 10 Index, is a self-report measure, consisting of 10 items that are scored on a fivepoint scale, ranging from 1 (not at all/never) to 5 (extremely/ never)

    Measured: one day

Secondary outcomes (3)
  1. Emotional adjustment

    STAI questionnaire

    Measured: one day

  2. Coping strategies use

    Kidcope checklist

    Measured: one day

  3. Social support

    Child and Adolescent Social Support Scale

    Measured: one day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Oct 2017
  2. Study start15 Mar 2020
  3. Primary completion1 May 2021
  4. Study completion1 May 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03299699
Sponsor's protocol ID
2017-06
Acronym
FRATHEMO
Status last verified
Jun 2023
First submitted
28 Sep 2017
Last updated
8 Jun 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Severe Haemophilia, run by Assistance Publique Hopitaux De Marseille at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Global quality of life (time frame: one day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in